Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gadjah Mada University
With
Dr. Sardjito Hospital, Yogyakarta
Furthermore, this clinical trial aims to:
* To determine the incidence of fever during the induction phase in pediatric ALL patients receiving levofloxacin prophylaxis compared with placebo.
* To determine the incidence of febrile neutropenia during the induction phase in pediatric ALL patients receiving levofloxacin prophylaxis compared with placebo.
* To determine the incidence of severe infections during the induction phase in pediatric ALL patients receiving levofloxacin prophylaxis compared with placebo.
* To determine the number of organ-related bacterial infections, whether microbiologically confirmed or not, during the induction phase in pediatric ALL patients receiving levofloxacin prophylaxis compared with placebo.
* To determine the mortality rate during the induction phase in pediatric ALL patients receiving levofloxacin prophylaxis compared with placebo.
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients aged 1 to 18 years diagnosed with acute lymphoblastic leukemia (ALL).
Receiving induction phase 1A chemotherapy for ALL using the Indonesian National Childhood ALL Pilot Protocol 2024 Standard Risk; induction phases 1A and 1B chemotherapy using the Indonesian National Childhood ALL Pilot Protocol 2024 High Risk; or induction chemotherapy using the ACT4ALL Protocol 2025 at Dr. Sardjito Hospital.
No history of allergy to levofloxacin.
Parents/guardians provide written informed consent.
You may not be if
Death before initiation of chemotherapy.
Patients with clinically or microbiologically confirmed infection within 72 hours prior to induction chemotherapy who require antibiotics for more than 5 days (to avoid antibiotic therapy as a confounding factor for antibiotic prophylaxis).